1
TITLE: Longer follow up of T-prolymphocytic leukaemia patients treated with Alemtuzumab (CAMPATH-1H) shows improved survival and higher response rates in previously untreated patients.
AUTHORS: Dearden, CE; Matutes, E; Cazin, B; Tjonnfiord, GE; Parreira, A; Leoni, P; Rassam, SMB; Roques, T; Ketterer, N; Lakhani, A; Catovsky, D;
PUBLISHED: 2002, SOURCE: 44th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 100, ISSUE: 11
INDEXED IN: WOS
2
TITLE: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
AUTHORS: Dearden, CE; Matutes, E; Cazin, B; Tjonnfjord, GE; Parreira, A; Nomdedeu, B; Leoni, P; Clark, FJ; Radia, D; Rassam, SMB; Roques, T; Ketterer, N; Brito Babapulle, V; Dyer, MJS; Catovsky, D;
PUBLISHED: 2001, SOURCE: BLOOD, VOLUME: 98, ISSUE: 6
INDEXED IN: Scopus WOS CrossRef
3
TITLE: Campath-1H treatment of T-prolymphocytic leukaemia (T-PLL).
AUTHORS: Dearden, CE; Matutes, E; Dyer, MJS; Leoni, P; Pareira, A; Lima, M; Tjonnifjord, GE; Nomdedeu, B; Catovsky, D;
PUBLISHED: 1999, SOURCE: BLOOD, VOLUME: 94, ISSUE: 10
INDEXED IN: WOS